Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Idera Pharmaceuticals Inc (IDRA): $2 Biotech Could be the Best Chance to Triple Your Money in This Market

The stock market has been on a topsy-turvy, downhill roller-coaster ride since the start of August when the high of 1,709 was hit in the S&P 500 and 15,658 on the Dow Jones Industrial Average.

Yet due to fundamental underlying support, such as the improvement in European economies, the Fed being unlikely to change its accommodative monetary policy, and overall solid corporate earnings, I retain my bullish stance on stocks until the end of 2013.

However, the market remains difficult to time in the short term. Just when stocks seemed to be gaining solid footing, the market was hit with a black swan event when a Syrian chemical warfare attack resulted in sabre-rattling by the United States and fears of a U.S. missile strike.

One way investors can help avoid the effects of black swan political and economic events is by seeking out sectors that are not highly correlated with the overall market. One such group that I am fond of trading is clinical-stage biotech stocks.

Everyone knows these biotech stocks are, by definition, volatile. But they also have very little correlation with the overall market. So when it is difficult to predict what the market will do next, I look into small biotech stocks in search of outperformance.

One biotech stock that has bucked this summer’s fear-driven sell-offs is Idera Pharmaceuticals Inc (NASDAQ:IDRA). Shares have rocketed over 300% since the beginning of May, rising from just over $0.50 to a 52-week high of $2.13 last week. Compare this performance to the lackluster overall market during this time frame and it paints a compelling picture for this little biotech stock.

Idera Pharmaceuticals Inc (NASDAQ:IDRA) is a clinical-stage biotechnology company that was founded in 1989. It specializes in the discovery and development of novel synthetic DNA- and RNA-based drugs. These drugs are targeted to treat autoimmune and inflammatory diseases, primarily psoriasis, lupus, asthma, allergies and different forms of cancer. The company has zero debt on the balance sheet and an enterprise value of $73 million.

In July, the company announced that it received a U.S. patent on its IMO-8400 drug, protecting both the composition and method of use. The product is the company’s lead contender for the treatment of autoimmune diseases, and it is currently being evaluated in a Phase II trial in patients with moderate-to-severe plaque psoriasis.

As in the case with most early stage biotech companies, Idera Pharmaceuticals Inc (NASDAQ:IDRA) has no earnings and incurs high expenses in the attempt to get products to market. But the company raised $16.5 million during the second quarter through a common stock offering. With cash and cash equivalents of $16.3 million, the company said it is confident it can complete the Phase II trials by the first quarter of 2014 and fund operations through the end of that year. This is a major positive for the stock.

Another substantial positive is that the recently appointed chairman of the board of directors, James Geraghty, purchased 300,000 shares at $1.75 for a total of $525,000.

Technically, Idera Pharmaceuticals Inc (NASDAQ:IDRA) looks like a screaming buy right now. The uptrend has been in full effect since May 1. Traders may want to wait for an intraday pullback or enter on upward momentum depending on their preferred method of trading.

IDRA Chart

Recommended Trade Setup:

— Buy Idera Pharmaceuticals Inc (NASDAQ:IDRA) on a pullback to $2 or a breakout above $2.25
— Set stop-loss at $1.70
— Set initial price target at $6 for a potential 167%-200% gain in nine months

$1,000 Per Month Trading System You could collect $1,000 or more per month without buying a single stock. Click here to learn how…

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.